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AUTHOR’S VIEW
Structure and function of a monocarboxylate transporter homolog specific for
L-lactate
Patrick D. Bosshart , David Kalbermatter , Sara Bonetti, and Dimitrios Fotiadis
Institute of Biochemistry and Molecular Medicine, and Swiss National Centre of Competence in Research (NCCR) TransCure, University of Bern, Bern,
Switzerland
ABSTRACT
Monocarboxylate transporters play important roles in certain cancers. We have reported structures of an
L-lactate-transporting solute carrier family 16 homolog with bound substrate and inhibitor. The struc-
tures show the transporter in the pharmacologically relevant outward-open conformation. Structure–
function analysis provides insights into the molecular working mechanisms of ligand binding and
L-lactate transport.
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The monocarboxylate L-lactate is generated during anaero-
bic carbohydrate breakdown and serves as fuel or building
block in different cell types. Certain monocarboxylate trans-
porters (MCTs) of the solute carrier 16 (SLC16) family
mediate stereospecific L-lactate transport across cell
membranes.1 Among the 14 mammalian SLC16 family mem-
bers, MCT1-4 were identified as L-lactate:proton symporters,
which are also able to transport other monocarboxylic meta-
bolites such as pyruvate and ketone bodies.1 Other members
of the SLC16 solute carrier family encode high-affinity thyr-
oid hormone (MCT8, SLC16A2) or aromatic amino acid
(MCT10, SLC16A10) transporters.2 The L-lactate transpor-
ters MCT1 and MCT4 form heterodimers with the glycopro-
teins embigin (also known as GP70) or basigin (also known
as CD147) that are essential for correct surface plasma
membrane expression.3,4
MCT1 (SLC16A1) is expressed in almost all tissues and
transports L-lactate into cells with a Michaelis constant (KM)
of 3–5 mM.1 MCT2 (SLC16A7) is mainly located in the brain,
kidney, liver, and testis, where it mediates inward-directed
L-lactate transport with a KM of ~0.7 mM.
1 In the retinal
pigment epithelium and in the choroid plexus epithelia,
L-lactate is exported by MCT3 (SLC16A8, KM of ~6 mM
5).
MCT4 (SLC16A3) is overexpressed in highly glycolytic and
anaerobic tissues, where the transcription of its gene is regu-
lated by the hypoxia-inducible factor 1α.1 These cells produce
large amounts of L-lactate, which must be efficiently exported
by MCT4 (KM of 20–35 mM).
1
MCTs 1 and 4 play important and complementary roles in
cancer metabolism. Due to metabolic disorder, certain tumor
cells cover their demand for ATP by increasing the rate of
glycolysis even under aerobic conditions (“Warburg effect”6).
The glycolytic phenotype is maintained if pyruvate is reduced
to L-lactate, thereby regenerating NAD+, which is utilized
during glycolysis. MCT4 exports the produced L-lactate
together with a proton and prevents its accumulation and
cellular acidification. In tumors, the acidification of the extra-
cellular microenvironment resulting from co-transported pro-
tons promotes angiogenesis, invasion, metastasis, and tumor
cell proliferation.6 Exported L-lactate can enter other cancer
cells via MCT1 to serve as fuel for proliferating cells.7
Consequently, MCT1 and MCT4 are promising drug targets
for treating certain tumors because their inhibition compro-
mises important metabolic processes. This fact is highlighted
by clinical trials involving an MCT1 inhibitor (see AZD3965
at http://www.clinicaltrials.gov) and a recent study that iden-
tified an approved antihypertension drug (syrosingopine) as
MCT4 inhibitor.8
The structure of an L-lactate transporter of the SLC16
family would enable us to understand the working mechanism
of this class of membrane proteins at a molecular level.
Furthermore, high-quality experimental structures are essen-
tial to build reliable homology models, which can be used for
structure-based design of specific L-lactate transport inhibi-
tors and to perform meaningful in silico ligand docking. For
this reason, an ambitious structural biology project was
launched in the Fotiadis laboratory (http://www.fotiadislab.
com) in 2012 with the goal to identify an L-lactate-
transporting member of the SLC16 family that can be
expressed in large quantities, homogenously purified, and
crystallized for structure solution by X-ray crystallography.
As a result, we have recently published the first high-
resolution structures of an L-lactate-transporting SLC16
family homolog from Syntrophobacter fumaroxidans
(SfMCT) with bound substrate (i.e. L-lactate) and inhibitor
(i.e. thiosalicylate) (Figure 1).9 SfMCT contains 12 transmem-
brane helices (TMs), and it adopts the characteristic fold of
membrane proteins belonging to the major facilitator
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superfamily. The helices are arranged in 2 six-helix bundles
that are related to each other by a pseudo-twofold symmetry
axis (Figure 1, left, broken gray line), which is perpendicular
to the membrane plane. Our structures show SfMCT in an
outward-open conformation where the substrate-binding site
is accessible from the extracellular side (Figure 1, left, high-
lighted by an asterisk). Residues that are involved in substrate
and inhibitor binding (Figure 1, right) were identified based
on our structural data and extensive functional characteriza-
tion. A conserved arginine residue in transmembrane helix 8
(R280) is essential for the binding of the carboxylate group of
substrates or inhibitors. Removal of the positively charged
guanidinium group leads to an inactive SfMCT variant. The
same transport deficiency has been observed if the corre-
sponding arginine was mutated in human MCT1, which is
associated with ketoacidosis.10 We have also identified resi-
dues in the binding pocket that seem to be involved in
regulating the substrate specificity and transport efficiency in
SfMCT. Furthermore, a hypothesis was provided on how
protons that are co-transported with lactate are captured by
proton binding site residues. From a pharmacological per-
spective, the observed outward-open conformation is relevant
for the future design of transport inhibitors using SfMCT-
based homology models of human MCT1 and MCT4.
In summary, we have identified a proton-coupled and
L-lactate-specific homolog of the SLC16 family, which is an
appropriate model for studying human MCT1-4. The structural
and functional data have provided important insights into the
molecular working mechanism of L-lactate transporters.
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charmm-gui.org). The two L-lactate molecules bound to SfMCT are displayed in black as space-filling models. The central, conical cavity that is open to the
periplasmic side (out) is highlighted by the asterisk, and the dark grey, vertical broken line represents the pseudo-twofold symmetry axis of SfMCT. Amino- and
carboxy-termini are labeled by “N” and “C”. Parts of the loops connecting transmembrane helices (TM) 1 and TM2, TM5 and TM6 as well as TM6 and TM7 could not
be fully traced and are therefore indicated by broken lines. The model of SfMCT is colored based on the rainbow coloring scheme from blue (amino-terminus) to red
(carboxy-terminus). Residues that are involved in the binding of L-lactate to SfMCT are shown in beige and are labeled by numbered one-letter codes (right).
Interactions with the main-chain carbonyl atoms are additionally labeled with (O). Two L-lactate molecules (Lac1 and Lac2) are found in the binding pocket and are
colored in black. Dotted lines represent hydrogen bonds.
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